-
Mashup Score: 1Haran Burri, EHRA 2021: Biological Pacemakers – touchCARDIO - 3 year(s) ago
Prof. Haran Burri (Lead Cardiac Physiologist, University of Oxford, Oxford, UK) spoke to us on the concept and the current status of biological pacemakers from the European Heart Rhythm Association (EHRA) Virtual Meeting 2021. Questions: Could you give us a brief overview of the concept of biological pacemakers and the current status of research? (0.21) […]
Source: touchCARDIOCategories: Cardiology News and Journals, Latest HeadlinesTweet
-
Mashup Score: 7Science Espresso - 3 year(s) ago
Your access to the latest cardiovascular news, science, tools and resources.
Source: www.escardio.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Have 10 minutes? Take a break and catch up on recent presentations from the recent #EHRA2021 and #EuroCMR congresses How to handle challenging LV lead implantations? Evaluation of ischaemic #heartdisease Enjoy your break https://t.co/6qT7M3KVTj #cardioed #cardiotwitter https://t.co/JeX9p8Bfdm
-
-
Mashup Score: 2
A prolonged course of antibiotic therapy lasting at least 28 days dramatically reduces the risk of recurrent cyst infection in patients with autosomal dominant polycystic kidney disease.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
A prolonged course of antibiotic therapy dramatically reduces the risk of recurrent cyst infection in patients with autosomal dominant polycystic kidney disease. https://t.co/FxRuD3Drwv #EHRA2021 https://t.co/iymJPDjG9r
-
-
Mashup Score: 1
A prolonged course of antibiotic therapy lasting at least 28 days dramatically reduces the risk of recurrent cyst infection in patients with autosomal dominant polycystic kidney disease.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
A prolonged course of antibiotic therapy dramatically reduces the risk of recurrent cyst infection in patients with autosomal dominant polycystic #kidneydisease. https://t.co/HW0uKhB9NT #EHRA2021
-
-
Mashup Score: 0No Extra Drop in AF Burden From Postablation Weight-Loss Program - 3 year(s) ago
Although weight loss may have benefited in one type of AF, tight risk-factor management in all patients, not just those assigned to intervention, may have blunted other outcomes differences.
Source: MedscapeCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Supervised Obesity Reduction Trial in #AtrialFibrillation Study Results: Assigning patients to a structured weight loss program after AF may not enhance the treatment’s effect on AF burden. https://t.co/nwHtTDQN9U #EHRA2021
-
-
Mashup Score: 1No Extra Drop in AF Burden From Postablation Weight-Loss Program - 3 year(s) ago
Although weight loss may have benefited in one type of AF, tight risk-factor management in all patients, not just those assigned to intervention, may have blunted other outcomes differences.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
Supervised Obesity Reduction Trial in Atrial Fibrillation Study Results: Assigning patients to a structured weight loss program after AF may not enhance the treatment’s effect on AF burden. https://t.co/kAMAlG7kfF #EHRA2021
-
-
Mashup Score: 0What's New for UK Cardiology Practice from EHRA 2021? - 3 year(s) ago
Dr Sukh Nijjer and guest discuss the key developments from the European Heart Rhythm Association (EHRA) Congress.
Source: MedscapeCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Key messages from #EHRA2021. https://t.co/lGNJOjvFdJ https://t.co/ufjzGNN7eL
-
-
Mashup Score: 1New-Onset Anxiety, Depression an Ongoing Risk for ICD Patients - 3 year(s) ago
Some risk factors in this study made sense, others were a bit counterintuitive. Surveillance beyond just initial testing may identify many first-time ICD patients who develop new depression or anxiety.
Source: MedscapeCategories: General Medicine News, Latest HeadlinesTweet-
Patients with implantable cardioverter defibrillators, have a 2% to 4% rate of new-onset anxiety and depression, not just in the early years after implantation, cautions new data. https://t.co/eEd4tV6PPX #EHRA2021
-
-
Mashup Score: 0Trade-offs Between S-ICD, Transvenous ICDs Shown in EFFORTLESS - 3 year(s) ago
The postmarket study’s “final report” depicted an evolving S-ICD experience that, for some, cast such limitations as a lack of shock-avoiding antitachycardia pacing in a softer contemporary light.
Source: MedscapeCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Trade-offs between subcutaneous, transvenous #ICDs on display in EFFORTLESS trial. https://t.co/BLUJZeS8ka #EHRA2021
-
-
Mashup Score: 1Trade-offs Between S-ICD, Transvenous ICDs Shown in EFFORTLESS - 3 year(s) ago
The postmarket study’s “final report” depicted an evolving S-ICD experience that, for some, cast such limitations as a lack of shock-avoiding antitachycardia pacing in a softer contemporary light.
Source: MedscapeCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Trade-offs between subcutaneous, transvenous ICDs on display in EFFORTLESS trial. https://t.co/OA7e3VwJbn #EHRA2021
-
RT @touchCARDIO: An overview of the concept of biological pacemakers and the current status of research - https://t.co/mNoonST2vX #ehra2021…